Physician profile
Raymond Lee Capps
NPI 1346444742
$151,823.08
in general payments reported to CMS, 2019-2025
47 companies · $588 in 2025
The $588 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,782 · 2020: $44K · 2021: $67K · 2022: $27K · 2023: $3,042 · 2024: $8,270 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,132 · Food and Beverage: $5,673 · Education: $96.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,131.62 |
| Food and Beverage | $5,672.68 |
| Education | $96.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $46,933.16 | 2021-2024 | Ubrelvy, Qulipta, Vraylar |
| Allergan, INC. | $42,680.19 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $16,119.11 | 2020-2021 | |
| Lilly USA, LLC | $12,332.30 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Biohaven Pharmaceutical Holding Company LTD. | $8,037.94 | 2022 | |
| Sk Life Science, INC. | $7,620.07 | 2020-2025 | |
| Biogen, INC. | $6,410.16 | 2019-2025 | Vumerity, Avonex, Tysabri |
| Lundbeck LLC | $2,120.03 | 2019-2024 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $1,461.83 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Ucb, INC. | $966.22 | 2019-2025 | Briviact, Fintepla, Zilbrysq |
| Neurocrine Biosciences, INC. | $642.05 | 2021-2025 | Ingrezza, Ongentys |
| Alexion Pharmaceuticals, INC. | $619.67 | 2019-2025 | Ultomiris |
| Mdd US Operations, LLC | $565.74 | 2019-2025 | Gocovri, Apokyn |
| Amgen INC. | $505.01 | 2019-2024 | Aimovig |
| Genentech USA, INC. | $405.09 | 2019-2024 | Ocrevus, Ocrevus Zunovo |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Capps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.